Rising Cancer Incidence Drives Growth In The Aurora Kinase B Market Is Supporting Development Across The Aurora Kinase B Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Aurora Kinase B Market Increase Between 2026 And 2030?

The aurora kinase b market size has experienced rapid expansion in recent years. It is anticipated to grow from $1.27 billion in 2025 to $1.43 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. The growth observed in the historic period can be attributed to several factors, including advancements in molecular oncology research, the identification of aurora kinase b as a specific target in cancer therapy, the broadening of clinical trial infrastructure, increased investment in targeted cancer therapies, and progress made in the development of kinase inhibitors.

The aurora kinase b market is poised for substantial growth in the upcoming years. It is projected to achieve a size of $2.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This anticipated expansion over the forecast period is primarily driven by factors such as the escalating demand for precision cancer therapeutics, the wider adoption of personalized medicine strategies, an increase in oncology clinical trial activities, growing investments in innovative kinase inhibitors, and improved regulatory support for targeted oncology drugs. Furthermore, significant trends expected during this period include the intensified development of selective aurora kinase b inhibitors, a greater emphasis on combination oncology therapies, the expansion of precision oncology drug pipelines, a rising focus on mitotic targeted therapies, and enhanced biomarker-based patient stratification.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

What Primary Factors Are Fueling The Expansion Of The Aurora Kinase B Market?

An anticipated increase in cancer cases is projected to boost the expansion of the aurora kinase B market in the future. Cancer encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells, capable of invading adjacent tissues and spreading to distant areas of the body. The escalating number of cancer diagnoses stems from elements like an aging demographic, shifts in lifestyle, environmental risk factors, and advancements in screening and identification. Aurora kinase B is crucial for cell division (mitosis), and elevated levels of its expression are associated with unstable chromosomes and the advancement of cancer. Given its participation in the division of tumor cells, it is frequently a focus for cancer treatments. For example, in February 2024, the World Health Organization, an intergovernmental body situated in Switzerland, reported approximately 20 million new cancer cases in 2022, alongside 9.7 million fatalities. Projections indicate that by 2050, new cancer cases will surpass 35 million, marking a 77% surge compared to 2022 figures. Consequently, the increasing prevalence of cancer is fueling the expansion of the aurora kinase B market.

Which Segment Groups Define The Aurora Kinase B Market Landscape?

The aurora kinase b market covered in this report is segmented –

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types

2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications

3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811

2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies

3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib

4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies

5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials

6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

What Trends Are Influencing The Aurora Kinase B Market Outlook?

Leading companies within the aurora kinase B market are actively engaged in developing innovative products, such as aurora kinase inhibitors, designed to specifically target and disrupt critical processes involved in cell division. Aurora kinase inhibitors are medications formulated to block the activity of Aurora kinases, which are essential for cell division, thereby impeding the proliferation of cancer cells and potentially reducing tumor growth. For instance, in June 2023, Ellipses Pharma, a biotechnology company based in the UK, announced the U.S. Food and Drug Administration (FDA) approval for its compound, EP0042, which functions as a dual FLT-3 and Aurora kinase inhibitor. EP0042 is currently being developed as a treatment for acute myeloid leukemia (AML) and operates by targeting both FLT3 and Aurora kinase. This specific approach is crafted for AML patients who have developed resistance to FLT3 inhibitors. Research has demonstrated that the dual inhibition of FLT3 and Aurora kinase can overcome acquired resistance to selective FLT3 inhibition in both in vitro and in vivo settings.

Who Are The Leading Firms Participating In The Aurora Kinase B Market?

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Access The Complete Aurora Kinase B Market Report:

https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Area Represents The Largest Portion Of The Aurora Kinase B Market?

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Aurora Kinase B Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

Browse Through More Reports Similar to the Global Aurora Kinase B Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795